Edwards Lifesciences (EW) Price Target Raised to $180.00

Share on StockTwits

Edwards Lifesciences (NYSE:EW) had its price objective upped by UBS Group from $175.00 to $180.00 in a research report report published on Tuesday morning, www.benzinga.com reports. UBS Group currently has a neutral rating on the medical research company’s stock.

Several other analysts have also commented on the stock. Citigroup lifted their price target on shares of Edwards Lifesciences from $118.00 to $119.00 and gave the company a sell rating in a research report on Wednesday, January 2nd. Bank of America raised shares of Edwards Lifesciences from a neutral rating to a buy rating and lifted their price target for the company from $180.00 to $190.00 in a research report on Friday, January 18th. Cowen set a $190.00 price target on shares of Edwards Lifesciences and gave the company a buy rating in a research report on Monday, December 10th. Deutsche Bank started coverage on shares of Edwards Lifesciences in a research report on Wednesday, January 2nd. They set a hold rating and a $164.00 price target on the stock. Finally, Credit Suisse Group started coverage on shares of Edwards Lifesciences in a research report on Monday, December 17th. They set an outperform rating and a $188.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have issued a buy rating to the company. The stock has an average rating of Buy and an average target price of $171.10.

EW stock opened at $178.02 on Tuesday. The company has a market cap of $36.45 billion, a PE ratio of 37.88, a PEG ratio of 2.26 and a beta of 0.90. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.92 and a current ratio of 2.61. Edwards Lifesciences has a one year low of $123.00 and a one year high of $178.69.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, January 31st. The medical research company reported $1.17 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $1.17. The firm had revenue of $977.70 million for the quarter, compared to analyst estimates of $973.72 million. Edwards Lifesciences had a net margin of 19.40% and a return on equity of 31.09%. During the same quarter in the previous year, the company earned $0.94 EPS. Analysts forecast that Edwards Lifesciences will post 5.21 earnings per share for the current year.

In related news, VP Huimin Wang sold 4,000 shares of the stock in a transaction dated Friday, January 4th. The shares were sold at an average price of $145.33, for a total transaction of $581,320.00. Following the completion of the transaction, the vice president now directly owns 35,224 shares of the company’s stock, valued at $5,119,103.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Michael A. Mussallem sold 32,800 shares of the stock in a transaction dated Friday, December 21st. The stock was sold at an average price of $146.03, for a total transaction of $4,789,784.00. Following the transaction, the chief executive officer now directly owns 75,926 shares of the company’s stock, valued at $11,087,473.78. The disclosure for this sale can be found here. Insiders sold 168,522 shares of company stock valued at $26,990,579 in the last 90 days. 1.84% of the stock is currently owned by insiders.

Several hedge funds have recently added to or reduced their stakes in the company. Executive Wealth Management LLC purchased a new position in Edwards Lifesciences during the fourth quarter worth approximately $25,000. Sontag Advisory LLC purchased a new position in shares of Edwards Lifesciences in the 4th quarter valued at $26,000. Lindbrook Capital LLC purchased a new position in shares of Edwards Lifesciences in the 4th quarter valued at $27,000. Capital Financial Planning LLC purchased a new position in shares of Edwards Lifesciences in the 4th quarter valued at $28,000. Finally, Nelson Roberts Investment Advisors LLC purchased a new position in shares of Edwards Lifesciences in the 4th quarter valued at $30,000. Institutional investors and hedge funds own 83.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Featured Article: What are the benefits of a balanced fund?

Analyst Recommendations for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Immersion  Upgraded by Zacks Investment Research to “Buy”
Immersion Upgraded by Zacks Investment Research to “Buy”
Superdry’s  “Hold” Rating Reiterated at Peel Hunt
Superdry’s “Hold” Rating Reiterated at Peel Hunt
Teekay Lng Partners  vs. EuroDry  Head-To-Head Comparison
Teekay Lng Partners vs. EuroDry Head-To-Head Comparison
Duke Energy  PT Set at $90.00 by JPMorgan Chase & Co.
Duke Energy PT Set at $90.00 by JPMorgan Chase & Co.
CNX Resources  Hits New 52-Week Low at $8.41
CNX Resources Hits New 52-Week Low at $8.41
Haymaker Acquisition  Coverage Initiated at Jefferies Financial Group
Haymaker Acquisition Coverage Initiated at Jefferies Financial Group


© 2006-2019 Ticker Report